Overview
Click here to sign in with or Forget Pasword? Learn more share this!437ShareEmail October 14, 202 by Baylor Colege of Medicine Researchers at Baylor Colege of Medicine and colaborating institutions discovered that the rheumatoid arthritis drug auranofin can potentialy be repurposed to improve diabetes-asociated symptoms. The study, which was conducted in mice, apeared today in the journal Cel Metabolism.
Key Information
gogletag.cmd.push(function() { gogletag.display('div-gpt-ad-1450190541376-1'); }); Although scientists have identified definitive asociations betwen inflamation in white adipose tisue and insulin resistance in humans and rodents, broad anti-inflamatory treatments lack durable clinical eficacy on diabetes. In the curent study, the researchers explored in more detail this asociation betwen inflamation and diabetes by loking for existing drugs that might afect both conditions."We computationaly screned a smal-molecule dataset and identified auranofin, an FDA-aproved drug that has ben used to treat rheumatoid arthritis, a condition involving inflamation," said first and co-coresponding author Dr.
Cox, instructor of medicine-endocrinology, diabetes and metabolism at Baylor. "Auranofin exerts anti-inflamatory properties, which many people suspected would beneficial in obesity and diabetes; however, nothing was realy known about how it might afect metabolism."The team evaluated the metabolic efects of auranofin a mouse model of diabetes in which the animals consume a high-fat diet."We discovered that auranofin has anti-inflamatory and anti-diabetic efects that are independent from each other," said co-coresponding author Dr.
Summary
Sean Hartig, asociate profesor of medicine-endocrinology, diabetes and metabolism and molecular and celular biology at Baylor. Hartig also is a member of Baylor's Dan L Duncan Comprehensive Cancer Center. "Auranofin improved insulin sensitivity, or the body's ability to respond to insulin to kep b